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Abstract
Background—No randomized trial has directly compared the efficacy of prolonged infant 
antiretroviral prophylaxis versus maternal antiretroviral therapy (mART) for prevention of mother-
to-child transmission throughout the breastfeeding period.
Setting—Fourteen sites in sub-Saharan Africa and India.
Methods—A randomized, open label strategy trial was conducted in HIV-1-infected women with 
CD4 counts ≥350 cells/mm3 (or ≥country-specific ART threshold if higher) and their 
breastfeeding HIV-1-uninfected newborns. Randomization at 6-14 days postpartum was to mART 
or infant nevirapine prophylaxis (iNVP) continued until 18 months post-delivery or breastfeeding 
cessation, infant HIV-1 infection, or toxicity, whichever occurred first. The primary efficacy 
outcome was confirmed infant HIV-1 infection. Efficacy analyses included all randomized mother-
infant pairs except those with infant HIV-1 infection at entry.
Results—Between June 2011-October 2014, 2431 mother-infant pairs were enrolled; 97% of 
women were WHO Clinical Stage I, median screening CD4 count 686 cells/mm3. Median infant 
gestational age/birthweight were 39 weeks/2.9 kilograms. Seven of 1219 (0.57%) and seven of 
1211 (0.58%) analyzed infants in the mART and iNVP arms, respectively, were HIV-infected 
(hazard ratio [HR] 1.0, 96% repeated confidence interval 0.3-3.1); infant HIV-free survival was 
high (97.1%, mART and 97.7%, iNVP, at 24 months). There were no significant differences 
between arms in median time to breastfeeding cessation (16 months) or incidence of severe, life-
threatening or fatal adverse events for mothers or infants (14 and 42 per 100 person-years, 
respectively).
Conclusion—Both mART and iNVP prophylaxis strategies were safe and associated with very 
low breastfeeding HIV-1 transmission and high infant HIV-1-free survival at 24 months.
Keywords
Breastfeeding; HIV-1; prevention of perinatal HIV-1 transmission; antiretroviral therapy (ART); 
nevirapine
Introduction
Substantial progress has been made towards preventing perinatal transmission of HIV-1 in 
the developing world, but questions remain as to the relative safety and efficacy of various 
Flynn et al. Page 2
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2019 April 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
antiretroviral regimens. In the Antepartum Component of a large randomized multi-country 
clinical trial, Promoting Maternal Infant Survival Everywhere (PROMISE), we showed 
maternal antiretroviral therapy (ART) during pregnancy and intrapartum can reduce 
perinatal HIV-1 transmission to ∼0.5% in sub-Saharan African settings.1 However, 
breastfeeding-associated HIV-1 exposure and potential transmission continues in breastfed 
HIV-exposed infants living in resource-limited settings. While WHO guidelines recommend 
that all HIV-1-infected pregnant women initiate life-long ART, adherence to ART, 
particularly postpartum, has proven to be a major challenge; postpartum viral rebound has 
been observed in 31% of women starting ART during pregnancy who had initial viral 
suppression and 22% of women receiving preconception ART had detectable viremia at first 
antenatal visit.2-4 Thus, evaluation of the safety and efficacy of alternative strategies, such as 
infant prophylaxis, to reduce postnatal infection remains important.5
Based on prior clinical trial data, two strategies have been shown to be safe and effective in 
preventing postnatal HIV-1 transmission: 1)providing ART to the lactating woman, thereby 
reducing breastmilk viral load; or 2)providing daily single-drug antiretroviral (ARV) 
prophylaxis to the breastfeeding infant, maintaining prophylactic infant ARV blood levels 
throughout the period of HIV-1 transmission risk.6-13 Prior studies, however, focused on 
interventions only given through the first 6 to 12 months of breastfeeding and there were 
additional late infections related to breastfeeding transmission when breastfeeding continued 
after prophylaxis stopped. Because increased morbidity and mortality have been associated 
with weaning compared to continued breastfeeding through the second year of life in HIV-1-
exposed infants, breastfeeding beyond 12 months, and interventions to reduce HIV-1 
transmission during breastfeeding will be required to maximize infant HIV-1-free survival.
14-16
A few studies have evaluated the safety and efficacy of prolonged maternal or infant 
prophylaxis, but only through 12 months.11, 12 No prior randomized trial has directly 
compared the efficacy and safety of prolonged infant ARV prophylaxis to maternal ART 
throughout the duration of breastfeeding into the second year of life. We report results from 
the PROMISE trial's Postpartum Component, which randomized breastfeeding HIV-1-
infected women with high CD4 cell count and their HIV-1-uninfected infants at 6-14 days 
postpartum to either maternal ART (mART) or infant nevirapine (iNVP) prophylaxis to 
prevent HIV-1 transmission during breastfeeding.
Methods
Study design and participants
PROMISE was a randomized, open-label strategy trial sponsored by the U.S. National 
Institutes of Health conducted at 14 health-facility-based research sites in seven countries: 
India (1 site), Malawi (2), South Africa (5), Tanzania (1), Uganda (1), Zambia (1) and 
Zimbabwe (3). HIV-1-infected postpartum women were recruited from two sources: women 
completing the PROMISE Antepartum Component1 and women first identified as HIV-1-
infected during active labor, and hence received no ARV during pregnancy (“late 
presenters”).
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The PROMISE Postpartum Component was designed to compare the relative efficacy and 
safety of mART versus daily iNVP prophylaxis for prevention of breastmilk HIV-1 
transmission. Women who intended to breastfeed and planned to remain in the study site 
area through 24 months postpartum were eligible. Randomization occurred at the 
postpartum week 1 (day 6-14 after delivery) visit. Inclusion criteria for women (within 30 
days prior to enrollment in the Postpartum Component) were: CD4 count ≥ 350 cells/mm3 
(or ≥ the country-specific ART initiation threshold if it was >350 cells/mm3); hemoglobin 
>7.0 grams/dL; white blood cell count (WBC) >1,500 cells/mm3;absolute neutrophil count 
(ANC) >750 cells/mm3; platelets >50,000 cells/mm3; alanine aminotransferase (ALT) ≤ 2.5 
× upper limit of normal (ULN); and estimated creatinine clearance of ≥60 mL/min. 
Inclusion criteria for infants were: ≤14 days of age; birthweight ≥2.0 kilograms; uninfected 
(negative HIV-1 nucleic acid test [NAT] on a specimen drawn prior to the week 1 visit); 
hemoglobin ≥10 g/dL; WBC ≥1,500 cells/mm3; ANC ≥750 cells/mm3; platelets ≥50,000 
cells/mm3; and ALT ≤2.5 × ULN. For multiple births, a mother-infant pair was enrolled only 
if all live infants could be enrolled. Exclusion criteria included positive infant HIV-1 NAT 
result on a specimen drawn prior to study entry or NAT result not available; or a life-
threatening condition.
Prior to obtaining informed consent and during follow-up, women were regularly informed 
of the current and evolving country-specific guidelines for preventing perinatal HIV-1 
transmission and for ART initiation and other options for prevention outside of PROMISE. 
The study was approved by local and collaborating institutional review boards and other 
relevant regulatory authorities; and was reviewed for safety and efficacy by an independent 
Data and Safety Monitoring Board (DSMB).
Randomization
Women enrolled in the PROMISE Antepartum Component1 continued their antepartum 
randomized regimen (zidovudine alone [ZDV] or ZDV/lamivudine [3TC]/lopinavir boosted 
with ritonavir [LPVr] or tenofovir [TDF]/emtricitabine [FTC]/LPVr)until assessment for the 
Postpartum Component at the postpartum week 1 visit (day 6-14 after delivery). Late-
presenting women who had not been enrolled in the PROMISE Antepartum Component 
were enrolled in labor or within 5 days after delivery; those in labor received intrapartum 
single-dose nevirapine (sdNVP) with a TDF/FTC tail until the postpartum week 1 visit. All 
infants received daily NVP through age 6 weeks as recommended by World Health 
Organization (WHO) guidelines.17
Mother-infant pairs were randomized at the week 1 postpartum visit to one of two 
prophylaxis regimens (in a 1:1 ratio): mART or iNVP. TDF/FTC/LPVr was the study-
preferred mART regimen. TDF/FTC fixed dose combination tablets containing 300 mg/200 
mg orally daily plus LPV/r fixed dose combination tablets, two tablets of 200 mg/50 mg 
orally twice daily were recommended dosage. Women who experienced intolerance, toxicity, 
or clinical, immunologic or virologic failure were allowed to receive other three ARV 
regimens selected by their provider. Infant NVP was prescribed using age-based NVP dosing 
(Birth to 6 Weeks - birth weight ≥ 2500 gm, 15mg and for birth weight 2000–2499 gm, 
10mg; >6 Weeks to 6 Months - 20mg; >6 Months to 9 Months - 30mg; >9 Months to 
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cessation of BF or 18 months, whichever is first - 40mg). Randomized regimen was 
continued until 42 days after last breastmilk exposure (two weeks following breastfeeding 
cessation, defined as no breastmilk exposure for >28 days) or age 18 months, whichever 
came first. Randomized regimen was discontinued early if infant HIV-1 infection was 
diagnosed or for severe toxicity. A web-based, central computer randomization system used 
permuted block allocation with stratification by country and the antepartum/intrapartum 
maternal ARV prophylaxis [maternal ART versus ZDV/sdNVP versus ZDV/sdNVP (late 
presenter) vs. none (late presenter)].18
Procedures
Maternal visits occurred at weeks 1 (6-14 days postpartum, entry), 6 and 14 postpartum, and 
then every 12 weeks through week 74 postpartum. General medical history and limited 
physical examination were obtained at each visit. Complete blood count (CBC) was 
performed at all visits and chemistry safety labs (alanine aminotransferase [ALT], aspartate 
aminotransferase [AST], creatinine, alkaline phosphatase, total bilirubin and albumin) were 
also obtained except at week 62. CD4 cell counts were done at all visits except week 6 
postpartum. Pregnancy tests were obtained if pregnancy was suspected. Infant visits 
occurred at postpartum weeks 1, 6, 10, 14, 18, 22 and 26, then every 12 weeks until week 
98, with a final visit at week 104. History and physical evaluation were performed at all 
visits. HIV-1 NAT, CBC, and stored plasma were collected at every visit except week 10; 
ALT was obtained at weeks 1 and 6. For infants randomized to iNVP, ALT was done at week 
26 and every 12 weeks while receiving NVP. An HIV-1 antibody test could be substituted 
for NAT if the infant was >18 months old and had ceased breastfeeding. Infants diagnosed 
with HIV infection were referred to the local treatment clinic to initiate ART; study follow–
up continued regardless of infection status.
Outcomes
The primary efficacy outcome was confirmed infant HIV-1 infection, defined as positive 
HIV-1 NAT from a specimen drawn at any post-randomization visit, confirmed by a positive 
HIV-1 NAT on a second specimen drawn at a subsequent time point. Cases of uncertain 
infant HIV-1 infection status were reviewed, blinded to arm assignment, by an independent 
four-member committee who made the definitive determination of infant HIV-1 infection 
status and timing. Infant HIV-1-free survival (infant alive and not HIV-1-infected) and infant 
death were secondary efficacy outcome measures. All HIV-1 NATs were performed in 
laboratories certified by the Division of AIDS (DAIDS) Virology Quality Assurance 
Program.
The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, 2004 
Version 1.0 (clarification August 2009) was used to grade adverse events.19 For women, the 
primary safety outcome was a composite of Grade 2 hematologic, renal, or hepatic 
abnormalities or Grade ≥3 adverse events or death, whichever occurred first. For infants, the 
primary safety outcome was a composite of Grade ≥3 adverse events or death, whichever 
occurred first. Secondary safety outcomes included the individual components of the 
primary composite outcomes.
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Statistical analysis
The original target sample size was 4650 mother-infant pairs (approximately 3100 from the 
Antepartum Component and approximately 1550 late presenters), providing ≥90% power to 
detect a difference between groups in cumulative postnatal transmission at breastfeeding 
cessation of approximately 3% versus 5%, with 2-sided Type I error of 5% and allowing for 
loss-to-follow-up (10%) and interim efficacy monitoring (3%). These projected cumulative 
postnatal transmission rates were anticipated based on the following information and 
assumptions: postnatal transmission rates through 6 months postpartum would be 
approximately 1-3% among early presenters (based on the MITRA20 and MITRA-PLUS21 
studies) and approximately 5-7% among late presenters (based on the SWEN7 and PEPI-
Malawi8 studies); late presenters would represent 33% of all study participants; the postnatal 
transmission rate would increase by an average of 0.35% per month after 6 months 
postpartum (half the estimated rate reported in a meta-analysis22); and a projected average 
breastfeeding duration across all sites of approximately 9 months.
In July 2014, due to slow accrual, the sponsor (NIAID) decided to stop enrollment to all 
PROMISE Components when the Antepartum Component reached its accrual target for 
breastfeeding women or on October 1, 2014, whichever came first. The sponsor's decision 
was based in part on revised power calculations that used using the same approach as the 
original power calculations but with the anticipated postnatal transmission rates updated 
based on the smaller observed percentage of late presenters enrolled (6%) and the longer 
observed median duration of breastfeeding (15 months). The revised power calculations 
indicated that a projected total accrual of 2436 mother-infant pairs by October 1, 2014 
would provide 85% power to detect a difference between groups in cumulative postnatal 
transmission at breastfeeding cessation of approximately 3.2% versus 6%.
All analyses used the intent-to-treat principle with one pre-specified exception: mother-
infant pairs who had a positive infant HIV-1 NAT result on a specimen drawn prior to or on 
the randomization date were excluded from the efficacy analyses. The risk period for the 
primary efficacy and safety analyses was the time from randomization until 56 days after the 
last exposure to breastmilk or 18 months postpartum, whichever came first. The risk period 
was extended until 24 months postpartum in secondary efficacy and infant safety analyses. 
The a priori analysis plan specified that the primary efficacy and safety analyses would be 
censored at the recommended minimum duration of breastfeeding at each enrolling site (at 
the time of the study design, this was 6 or 12 months), due to concerns that the PROMISE 
post-breastfeeding maternal randomization of mART women to continue or stop mART 
could induce longer breastfeeding in the mART arm, which could introduce bias. Sensitivity 
analyses were also conducted which did not censor at the recommended minimum duration 
of breastfeeding.
Comparisons between randomization arms and estimation of effect sizes used time-to-event 
analyses with the Cox proportional hazards regression model. The distributions of time until 
the first event occurred were summarized using Kaplan-Meier plots. Statistical significance 
was defined as a two-sided p-value <0.05 for all analyses except efficacy; efficacy analyses 
used a group-sequential repeated confidence interval (RCI) for the hazard ratio in cumulative 
postnatal transmission using the Lan-DeMets approach with an O'Brien-Fleming Type 1 
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error spending function (for the final analysis, the confidence coefficient was 96%, to 
preserve an experiment-wise Type I error rate of 0.05). The RCI indicated the range of 
hazard ratio values that were consistent with the observed data; if the RCI excluded 1.0, this 
would indicate a statistically significant difference between arms and if the RCI included 
1.0, the width of the RCI would indicate the ability of the study to rule out a difference 
between treatment arms (the narrower the RCI, the stronger the evidence of 
equivalence).Two interim efficacy analyses were performed during the conduct of the study.
On July 7, 2015, the sites were instructed to inform all maternal participants about the 
START trial results23, which demonstrated statistically significant benefits of starting ART 
early compared to delayed initiation, and offer ART to those who were not receiving it. In 
November 2015, the DSMB recommended that the primary PROMISE analyses should 
include only follow-up through July 6 to minimize bias if large numbers of women in the 
iNVP arm chose to start ART or the women who chose to take ART were systematically 
different than those who did not. Statistical analyses were performed using SAS software 
version 9.4 (SAS Institute, Cary, NC).
Results
Between June 6, 2011 and October 1, 2014, a total of 2431 mother-infant pairs (including 13 
pairs of twins) were enrolled (1220 randomized to mART and 1211 to iNVP) from sites in 
Malawi (32%), South Africa (23%), Zimbabwe (22%), Uganda (16%), Zambia (2%), 
Tanzania (2%), and India (3%). Ninety-five percent of mother-infant pairs in each arm were 
previously enrolled in the PROMISE Antepartum Component (42% randomized to Maternal 
ZDV Arm and 53% randomized to a Maternal Triple ARV Arm) and 5% were late-
presenting women enrolled at delivery or within 5 days after delivery. Nearly all (1207, 
98.9%) of the mothers in the mART arm started the preferred study-supplied mART regimen 
and nearly all (1204, 98.9%) of the infants in the iNVP arm started on daily NVP.A patient 
flow diagram is shown in Supplemental Digital Content.
Table 1 summarizes selected baseline characteristics of mothers and infants at study entry. 
The median time to breastfeeding cessation was 16 months (70 weeks) with no statistically 
significant difference between arms (p=0.70).Kaplan-Meier probability estimates for 
continued breastfeeding at age 6, 9, 12, 18, and 24 months were 93.3%, 86.2%, 81.0%, 
34.3%, and 12.5%, respectively.
The efficacy analysis included 2430 of the 2431 enrolled mother-infant pairs (one infant 
born to a late-presenting mother was found to have been HIV-1-infected at time of 
randomization and was excluded from the efficacy analysis). Thirty-five infants (22 in the 
mART and 13 in the iNVP arm, 1.5%) had no post-randomization HIV-1 testing results and 
were censored at the date of randomization; 10 of the infants (6 mART and 4 iNVP) died of 
non-HIV (5 infants) or unknown causes (5 infants) without any record of HIV testing, 10 (7 
mART and 3 iART) were not able to get to clinic, 9 (6 mART and 3 iNVP) had consent 
withdrawn, and 6 (3 mART and 3 iNVP) could not be contacted (Supplemental Digital 
Content). Maternal and infant baseline characteristics (maternal RNA and CD4, infant 
gestational age and birthweight) were similar for the 22 mART and 13 iNVP arm infants.
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Eighteen infants were diagnosed with HIV-1 infection at a post-randomization visit; 14 were 
included in the primary analysis (4 were censored at the country recommended minimum 
duration of breastfeeding: 6 months for one and 12 months for three infants) and all were 
included in the secondary analysis through 24 months postpartum.
In the primary analysis, infant HIV-1 infection occurred in seven infant of 1219 mother-
infant pairs randomized to mART and seven of 1211 randomized to iNVP. The HIV-1 
transmission rates in both arms were much lower than anticipated and the 96% RCI was 
quite wide (0.3-3.1), indicating very limited ability to rule out differences between arms due 
to the small numbers of infants who were HIV-1 infected (Figure 1A, Table 2). Sensitivity 
analyses that did not censor at the minimum recommended duration of breastfeeding gave 
similar results (not shown).
In the secondary analysis, which included all follow-up data, there were eight cumulative 
infections among 1218 mother-infant pairs randomized to mART and 10 among the 1211 
randomized to iNVP. For the 18 infected infants, the median infant age at HIV-1 infection 
was 38 weeks (range, 13 – 62 weeks) in the mART arm and 50.5 weeks (range, 6 – 75 
weeks) in the iNVP arm. The cumulative probability of infection at 24 months was 0.9% 
(95%CI 0.6-1.5%) (Figure 1B, Table 2). The probability of infant HIV-1 infection/death at 
24 months in the mART arm was 2.9% (95% CI 2.0-4.1%), and in the iNVP arm was 2.3% 
(95% CI 1.5-3.4%), resulting in HIV-1-free survival at 24 months of 97.1% in the mART 
and 97.7%in the iNVP arm (Figure 1C, Table 2).
All 2431 women are included in the safety analysis; 15 had no post-randomization visit 
(nine in mART and six in iNVP) and were censored at date of randomization. There was no 
significant difference in time to the first composite safety endpoint between arms (p=0.98 
and p=0.61) and the incidence rates of adverse events were similar in the two arms (Table 3). 
Sensitivity analyses that did not censor at the minimum recommended duration of 
breastfeeding gave similar results (not shown). Three maternal deaths occurred (two in the 
mART and one in the iNVP arm) during the perinatal HIV-1 transmission risk period; no 
death was judged related to study intervention. Of the 1207 women in the mART arm who 
started on the study recommended regimen, 9 (<1%) stopped the recommended regimen 
because of toxicity.
All 2444 infants are included in the safety analysis; 4 had no post-randomization visit 
information (2 in each arm) and were censored at date of randomization. There was no 
significant difference in time to the first composite safety endpoint between arms (p=0.99) 
and the incidence rates of adverse events were similar in the two arms (Table 3). Sensitivity 
analyses that did not censor at the minimum recommended duration of breastfeeding gave 
similar results (not shown). Additionally, among infants randomized to iNVP, safety 
assessments beyond week 6 did not demonstrate increased incidence of liver or skin toxicity 
compared to the mART arm (Table 3). Of the 1204 infants in the iNVP arm who started on 
the study recommended regimen, 20 (<2%) stopped the recommended regimen because of 
toxicity.
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Thirty infant deaths occurred within the minimum recommended breastfeeding duration, and 
an additional eight thereafter (Table 3). Of the 30 deaths in the primary analysis, 16 were 
infants randomized to mART (incidence rate 1.2 per100 person-years; 95%CI 1.0-1.5 per 
100 person-years) and 14 in infants randomized to iNVP (incidence rate 1.1 per 100 person-
years; 95%CI 0.9-1.3 per 100 person-years), and not significantly different between arms 
(p=0.72). The Kaplan-Meier estimates of probabilities of infant death at 6, 9, 12, and 18 
months postpartum were 1.0% (95% CI 0.6-1.5%), 1.1% (95% CI 0.7-1.6%), 1.1% (95% CI 
0.7-1.6%), and 1.7% (95% CI 1.1-2.6%), respectively. The secondary analysis included all 
38 infant deaths (23 in the mART and 15 in the iNVP arm); and the cumulative probability 
of infant death at 24 months was 1.7% (95% CI 1.3-2.4%).No infant death was attributed to 
study regimen and no HIV-1-infected infant died.
Discussion
The PROMISE study is the first randomized trial to conduct a head-to-head comparison of 
mART and iNVP for postnatal HIV-1 transmission through up to 18 months of breastfeeding 
in asymptomatic women with high CD4 counts who did not meet treatment criteria at the 
time the study was conducted. While the cumulative postnatal HIV-1 transmission rates in 
both the mART and iNVP arms were much lower than anticipated in sample size 
calculations, which greatly limited the study's statistical power to detect a difference in 
transmission risk between arms, the findings demonstrate that both mART and iNVP 
regimens were highly efficacious, with 12- and 24-month postnatal infection rates of 0.6% 
and 0.9% and high rates of HIV-1-free survival at 24 months (>97%). The high under-two 
year survival rates (1.7% infant mortality) was particularly noteworthy compared to 
prevailing rates in most of the settings where the study was conducted.24
Two contemporary studies, ANRS 12174 and the Uganda PROMOTE trial demonstrated 
similar survival rates but at 50 weeks of follow-up. ANRS 12174 randomized HIV-1-
uninfected breastfed infants to either LPV/r or 3TC through cessation of breastfeeding or 50 
weeks. HIV-1-free survival at 50 weeks was 96% in both study arms.11 HIV-1-infected 
women in the PROMOTE study were randomized between 12 and 28 weeks of pregnancy to 
either a LPV/r or efavirenz based regimen that was continued for 48 weeks of breastfeeding. 
HIV-1-free infant survival at 8 weeks postpartum was 92.9% in the LPVr arm and 97.2% in 
the efavirenz arm.12
HIV-1 transmission rates in these studies were also low. In the PROMOTE study, HIV-1 
infection occurred during breastfeeding in one infant in the LPV/r arm. Infections rates after 
50 weeks in the ANRS 12174 study were 1.4% in the LPV/r arm and 1.5% in the 3TC arm. 
To date, there is only one study that has compared the efficacy of mART and infant 
prophylaxis. The Breastfeeding, Antiretrovirals and Nutrition Study (BAN) compared a 
control regimen of intrapartum sdNVP plus 7 days of ZDV/3TC in all women followed by a 
randomization into one of three groups: extended mART prophylaxis or daily iNVP 
prophylaxis given for up to 7 months of exclusive breast feeding or no further ARV 
prophylaxis in mothers nor infants. Although not designed nor powered to directly compare 
the efficacy of mART and iNVP, study findings indicated that both mART and the iNVP 
arms were superior to the one-week control arm (3%, 1.8% and 6.4%, respectively) at 28 
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weeks post-delivery.10 It should be noted the women in BAN received only sdNVP and 7 
days of ZDV/3TC as prophylaxis for perinatal transmission whereas 95% of the PROMISE 
cohort had been followed in the antepartum component and received either mART or ZDV. 
In addition, women in the BAN study were only enrolled if their CD4 count was greater than 
or equal to 200 or 250 cells/mm3 (depending on time of enrollment) whereas women 
enrolled in the PROMISE cohort had CD4 cell counts ≥ 350 cells/mm3 (or ≥ the country-
specific ART initiation threshold if it was >350 cells/mm3). These underlying differences in 
subject selection likely explain the higher HIV transmission rates observed in the BAN 
study.
Additionally, no safety concerns were observed in both mART and iNVP arms of the study. 
Less than 1% of women and 2% of infants discontinued their study regimen because of 
toxicity. Concerns have been raised about the potential infant toxicity from ingestion of 
ARVs in breastmilk of mothers receiving ART. Our study found no evidence of increased 
rates of toxicity in breastfeeding infants of mothers receiving tenofovir-based ART 
compared to breastfeeding infants whose mothers were not receiving ART. These data are 
also reassuring regarding the safety of TDF/FTC pre-exposure prophylaxis by breastfeeding, 
uninfected women at risk of HIV and their infants.25-27 Similarly, the prolonged use of daily 
NVP prophylaxis by HIV-1-uninfected infants for up to 18 months was not associated with 
elevated infant toxicity, including skin and liver toxicity, compared to infants not receiving 
NVP.
The median infant age to breastfeeding cessation in the study was 16 months, with 86% of 
infants still not having achieved complete breastfeeding cessation by 9 months, decreasing to 
34% by 18 months. This is longer than what was originally hypothesized during the design 
of the trial and likely reflects changing guidelines on breastfeeding by HIV-1-infected 
women as well as changing habits among sub-Saharan women during the trial. This 
prolonged duration of breastfeeding puts the HIV-1-exposed infant at risk of infection 
should there be suboptimal ART adherence by the mother. Approximately 67% of infections 
occurred after age 6 months, and 33% after age 12 months, with infections continuing to 
occur through 24 months.
During the conduct of the PROMISE randomized trial, the WHO guidelines for prevention 
of perinatal HIV-1 transmission were modified in 2013 to recommend maternal ART 
through at least the duration of breastfeeding; current guidelines recommend life-long ART 
for all HIV-1-infected individuals, including pregnant and breastfeeding women.17,28 
Despite these recommendations, due to postpartum adherence problems, many women 
experience rebound viremia, resulting in continued postnatal transmission.3,4,29 The 
PROMISE data demonstrate mART and iNVP have similar efficacy and safety profiles 
through up to 24 months of breastfeeding, indicating that while treatment for breastfeeding 
women is a priority, prolonged use of iNVP is an effective and safe alternative, for example, 
for women who refuse or do not adhere to ART, have persistent viremia, or who temporarily 
stop ART for toxicity.5 However, for women who refuse or are not adherent to ART, similar 
barriers to iNVP administration may exist.
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Our data underline the importance of providing postpartum support for women receiving 
ART, since we observed a continuing risk of infant postnatal infection for the duration of 
breastfeeding even when effective interventions were being provided. A variety of 
approaches will be needed to achieve an HIV-1-free generation, including interventions to 
support ART adherence and postpartum retention in care for women and ensuring the 
availability of equally effective and safe infant prophylaxis alternatives for situations in 
which maternal ART may be insufficient to protect the breastfeeding infant.
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Figure. 1
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Table 1
Baseline Characteristics of Women and Infants by Study Arm
Maternal Characteristic Maternal ART (N=1,220) Infant NVP 
Prophylaxis 
(N=1,211)
Total (N=2,431)
Age (years) Median (IQR) 26 (23-30) 26 (23-30) 26 (23-30)
Race Black African 1,178 (97%) 1,168 (96%) 2,346 (97%)
Asiana 41 (3%) 42 (3%) 83 (3%)
Coloured 1 (0%) 1 (0%) 2 (0%)
Weight (kg) # missing 0 0 0
Median (IQR) 61.0 (54.9-69.8) 61.0 (54.7-69.1) 61.0 (54.8-69.4)
Previous PROMISE Treatment Arm Antepartum Component 
– LPV/r + ZDV/3TC
508 (42%) 497 (41%) 1,005 (41%)
Antepartum Component 
– LPV/r + TDF/FTC
140 (11%) 149 (12%) 289 (12%)
Antepartum Component 
– ZDV +sdNVP
506 (41%) 503 (42%) 1,009 (42%)
Late Presenter 
Component - None
42 (3%) 39 (3%) 81 (3%)
Late Presenter 
Component – 
Intrapartum ZDV + 
sdNVP
24 (2%) 23 (2%) 47 (2%)
Gestational Age at Antepartum 
Randomization
# missing (includes late 
presenters)
67 62 129
Median (IQR) 26.3 (21.4-30.7) 26.3 (21.7-31.4) 26.3 (21.6-31.1)
HIV-1 Viral load (copies/ml) 
(obtained at Delivery or Entry Visit 
(Week 1 postpartum)
# missing 2 3 5
Median (IQR) 220 (40-1029) 400 (40-1960) 322 (40-1422)
Below assay limit of 
detection
499 (41%) 379 (31%) 878 (36%)
<400 276 (23%) 296 (24%) 572 (24%)
400 – 1,000 136 (11%) 139 (11%) 275 (11%)
1,000 - <10,000 196 (16%) 278 (23%) 474 (19%)
10,000 - <100,000 91 (7%) 105 (9%) 196 (8%)
100,000 - <200,000 12 (1%) 9 (1%) 21 (1%)
>=200,000 10 (1%) 5 (0%) 15 (1%)
Screening CD4 count (cells/mm3) Median (IQR) 682.5 (555-870) 691 (550-868) 686 (553-869)
350 - < 400 37 (3%) 49 (4%) 86 (4%)
400 - < 450 70 (6%) 57 (5%) 127 (5%)
450 - < 500 88 (7%) 90 (7%) 178 (7%)
500 - < 750 550 (45%) 522 (43%) 1,072 (44%)
≥ 750 475 (39%) 493 (41%) 968 (40%)
WHO Clinical Stageb Clinical Stage I 1,174 (96%) 1182 (98%) 2356 (97%)
Clinical Stage II 45 (4%) 28 (2%) 73 (3%)
Clinical Stage III 1 (0%) 1 (0%) 2 (0%)
# of live infants at entry 1 1,213 (99%) 1,205 (100%) 2,418 (99%)
2 7 (1%) 6 (0%) 13 (1%)
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Maternal Characteristic Maternal ART (N=1,220) Infant NVP 
Prophylaxis 
(N=1,211)
Total (N=2,431)
Infant Characteristic Maternal ART (N=1,227) Infant NVP 
Prophylaxis 
(N=1,217)
Total (N=2,444)
Gender Male 622 (51%) 614 (50%) 1,236 (51%)
Female 605 (49%) 603 (50%) 1,208 (49%)
Gestational age at birth (weeks) # missing 0 0 0
Median (IQR) 39 (38-40) 39 (38-40) 39 (38-40)
< 34 10 (1%) 8 (1%) 18 (1%)
34 - < 37 113 (11%) 135 (11%) 268 (11%)
≥ 37 1,084 (88%) 1,074 (88%) 2,158 (88%)
Birth weight (gm)c # missing 9 6 15
Median (IQR) 2,910 (2,600-3,230) 2,900(2,600-3,200) 2,900 (2,600-3,200)
2000 - <2500 149 (12%) 183 (15%) 332 (14%)
≥ 2,500 1,069 (88%) 1,028 (85%) 2,097 (86%)
a
Include women from the Indian subcontinent and natives of India
b
Two women had WHO Stage III at entry, but were tuberculosis-negative and had CD4 >350 copies/ml and therefore, did not require ART for their 
own health.
c
The birth weight is the infant weight closest to birth and within 0-5 days postpartum. Using the determination closest to birth (not restricting to 0-5 
days postpartum) gave similar summary statistics. All infants had weight of at least 2,000 grams.
3TC: lamivudine; ART: antiretroviral therapy; ARV: antiretroviral; FTC: emtricitabine; LPV/r: lopinavir boosted with ritonavir; NVP: nevirapine; 
sdNVP: single-dose nevirapine; TDF: tenofovir disoproxil fumarate; ZDV: zidovudine
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Table 2
Probability of HIV-1 Infection or HIV-1 Infection/Death by Study Arm: Primary and 
Secondary Analyses
Age Maternal ART Infant NVP Prophylaxis Overall
Probability of HIV-1 Infection % (95% Confidence Interval)
Primary analysis (Follow-up time is censored per planned analysis specifications)a
6 months 0.3% (0.1-0.8%) 0.3% (0.1-0.8%) 0.3% (0.1-0.6%)
9 months 0.6% (0.3%-1.3%) 0.3% (0.1-0.9%) 0.5% (0.2-0.8%)
12 months 0.7% (0.3-1.4%) 0.6% (0.3-1.3%) 0.6% (0.4-1.1%)
18 months 0.7% (0.3-1.4%) 0.9% (0.4-2.3%) 0.8% (0.4-1.5%)
Secondary analysis (Includes all infections and total duration follow-up)b
24 months 0.7% (0.4-1.5%) 1.1% (0.6-2.1%) 0.9% (0.6-1.5%)
Probability of HIV-1-Infection or Death % (95% Confidence Interval)
Secondary analysis (includes all infections and total duration follow-up)b
6 months 1.2% (0.7-2.0%) 1.2% (0.8-2.1%) 1.2% (0.8-1.7%)
9 months 1.7% (1.1-2.6%) 1.3% (0.8-2.2%) 1.5% (1.1-2.1%)
12 months 1.8% (1.2-2.7%) 1.6% (1.0-2.5%) 1.7% (1.2-2.3%)
18 months 2.4% (1.6-3.5%) 2.3% (1.5-3.4%) 2.3% (1.8-3.1%)
24 months 2.9% (2.0-4.1%) 2.3% (1.5-3.4%) 2.6% (2.0-3.4%)
a
Primary analysis: post-randomization to end of transmission risk period, 18 months postpartum, or minimum recommended duration of 
breastfeeding at site (whichever occurs first)
b
Secondary analysis: post-randomization to 24 months postpartum
ART: antiretroviral therapy; NVP: nevirapine
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Table 3
Numbers of Women and Infants who Experienced Adverse Events by Study Arm 
(Primary Analysis: Randomization to End of Transmission Risk Period, 18 Months 
Postpartum, or the Minimum Recommended Duration of Breastfeeding, Whichever came 
First)
Adverse Event Maternal ART Infant NVP Total
Women N=1211 N=1205 N=2416
Composite (Grade >3 adverse events or Grade 2 laboratory or death)a 159 (13.1%) 161(13.4%) 320 (13.2%)
Composite (Grade >3 adverse events/laboratory or death)b 59 (4.9%) 66 (5.5%) 125 (5.2%)
Death 2 (0.2%) 1 (0.1%) 3 (0.1%)
Grade >3 signs/symptoms 22 (1.8%) 24 (2.0%) 46 (1.9%)
Grade >2 laboratory 141(11.6%) 140 (11.6%) 281 (11.6%)
Grade >2 hematology 128 (10.6%) 119 (9.9%) 247 (10.2%)
Grade >2 chemistry 18 (1.5%) 27 (2.2%) 45 (1.9%)
Grade >3 laboratory 38 (3.1%) 42 (3.5%) 80 (3.3%)
Grade >3 hematology 35 (2.9%) 27 (2.2%) 62 (2.6%)
Grade >3 chemistry 3 (0.2%) 15 (1.2%) 18 (0.7%)
Infant N=1225 N=1215 N=2440
Composite (Grade >3 adverse events or death)c,d 427 (34.9%) 426 (35.1%) 853 (35.0%)
Death 16 (1.3%) 14 (1.2%) 30 (1.2%)
Grade >3 signs/symptoms 61 (5.1%) 44 (3.6%) 105 (4.3%)
Grade >3 laboratoryd 383 (31.3%) 385 (31.7%) 768 (31.5%)
Grade >3 hematology 383 (31.3%) 384 (31.6%) 767(31.4%)
Grade >3 chemistryd 0 (0%) 2 (0.2%) 2 (0.1%)
Grade ≥3 ALT (weeks 1 and 6 assessment) 0 (0%) 2 (0.2%) 2 (0.1%)
Grade ≥3 ALT (week 26, 28, 50, 62, and 74 assessment) NA 5 (0.4%) NA
a
Incidence rates were 14.4 per 100 person-years (95% CI 12.4-16.6 per 100 person-years) in women in the mART arm and 14.1 per 100 person-
years (95% CI 12.2-16.3 per 100 person-years) in women in the iNVP arm, and not significantly different between arms (p=0.98).
b
Incidence rates were 5.0 per 100 person-years (95% CI 4.2-5.9 per 100 person-years) in mART and 5·4 per 100 person-years (95% CI 4.6-6.4 per 
100 person-years) in iNVP, and not significantly different between arms (p=0.61).
c
Incidence rates were 42.5 per 100 person-years (95% CI 37.9-47.5 per 100 person-years) for infants in the mART and 42.0 per 100 person-years 
(95% CI 37.5-47.0 per 100 person-years) in infants in the iNVP arm, and not significantly different between arms (p=0.99).
d
Includes ALT from week 1 and 6 visit only since infants randomized to the mART arm did not have ALT assessed at subsequent study visits.
ALT: alanine aminotransferase; ART: antiretroviral therapy; NVP: nevirapine
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